YIPF3

Across TCGA pan-cancer cohorts, YIPF3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated YIPF3 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher YIPF3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated YIPF3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, LAML, and STAD are the cancer types where YIPF3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.112	0.743	<.001	28	view →
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →
STAD	OS	Median	III,IV	0.003	0.633	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.630	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

YIPF3–LUSC (OS)

Open the LUSC breakdown →